Elite Pharmaceuticals announced the US Food and Drug Administration’s acceptance for review of an Abbreviated New Drug Application on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELTP: